CKD Bio Corp.

As of June 30, 2026, CKD Bio Corp. carries a market capitalization of 72.14B, placing it among publicly traded companies globally. Its enterprise value stands at 219.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CKD Bio Corp.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, CKD Bio Corp. has 5.49M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.46, and the price-to-book ratio stands at 0.60.

As of June 30, 2026, CKD Bio Corp. trades at an EV/EBITDA multiple of 28.03 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.39 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 219.49B versus a market cap of 72.14B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, CKD Bio Corp. maintains a current ratio of 1.06, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 123.73, indicating elevated leverage, while an interest coverage ratio of 1.39 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, CKD Bio Corp. posted a negative return on equity (ROE) of -8.58, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.67, reflecting losses generated across the asset base. The company generates approximately 300.04M in revenue per employee across its workforce of 527.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.56 indicates how many times CKD Bio Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, CKD Bio Corp. recorded an income tax benefit of -189.97M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -10.93B and -10.74B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, CKD Bio Corp.'s stock has declined approximately 41.59% over the past 52 weeks. The 50-day moving average sits at 13,480.00, while the 200-day moving average is 16,819.80.

Over the twelve months ended June 30, 2026, CKD Bio Corp. generated 158.12B in revenue and converted that into -10.74B in net income, yielding earnings per share of -1,958.09. EBITDA reached 7.83B, while operating income came in at -8.07B.

As of June 30, 2026, CKD Bio Corp. holds 587.63M in cash and equivalents against 147.94B in total debt, resulting in a net debt position of 145.83B. Total book value stands at 119.57B, with working capital of 7.42B providing operational flexibility.

CKD Bio Corp. produced 1.01B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10.85B in capital expenditures, free cash flow totaled -9.84B - equivalent to -1,794.18 per share.

Over the twelve months ended June 30, 2026, CKD Bio Corp. posted a gross margin of 10.86, reflecting its pricing power and cost economics. The operating margin of -5.10 and net profit margin of -6.79 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, CKD Bio Corp. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -13.64: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -12.49, meaning CKD Bio Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

CKD Bio Corp.'s most recent stock split took place on December 27, 2019 with a 20:21 split ratio.

As of June 30, 2026, CKD Bio Corp. has an Altman Z-Score of 1.11, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.